Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
ScripWho: Genentech/COUR Pharmaceuticals What: Roche subsidiary Genentech entered into a collaboration and licensing agreement with COUR Pharmaceuticals to develop and commercialize COUR’s tolerogenic n